|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Trends in treatment and overall survival among patients with proximal esophageal cancer显示文摘BACKGROUND The management of proximal esophageal cancer differs from that of tumors located in the mid and lower part of the esophagus due to the close vicinity of vital structures.Non-surgical treatment options like radiotherapy and definitive chemoradiation(CRT)have been implemented.The trends in(non-)surgical treatment and its impact on overall survival(OS)in patients with proximal esophageal cancer are unclear,related to its rare disease status.To optimize treatment strategies and counseling of patients with proximal esophageal cancer,it is therefore essential to gain more insight through real-life studies.AIM To establish trends in treatment and OS in patients with proximal esophageal cancer.METHODS In this population-based study,patients with proximal esophageal cancer diagnosed between 1989 and 2014 were identified in the Netherlands Cancer Registry.The proximal esophagus consists of the cervical esophagus and the upper thoracic section,extending to 24 cm from the incisors.Trends in radiotherapy,chemotherapy,and surgery,and OS were assessed.Analyses were stratified by presence of distant metastasis.Multivariable Cox proportional hazards regression analyses was performed to assess the effect of period of diagnosis on OS,adjusted for patient,tumor,and treatment characteristics.RESULTS In total,2783 patients were included.Over the study period,the use of radiotherapy,resection,and CRT in non-metastatic disease changed from 53%,23%,and 1%in 1989-1994 to 21%,9%,and 49%in 2010-2014,respectively.In metastatic disease,the use of chemotherapy and radiotherapy increased over time.Median OS of the total population increased from 7.3 mo[95%confidence interval(CI):6.4-8.1]in 1989-1994 to 9.5 mo(95%CI:8.1-10.8)in 2010-2014(logrank P<0.001).In non-metastatic disease,5-year OS rates improved from 5%(95%CI:3%-7%)in 1989-1994 to 13%(95%CI:9%-17%)in 2010-2014(logrank P<0.001).Multivariable regression analysis demonstrated a significant treatment effect over time on survival.In metastatic disease,median OS was 3.8 mo(95%CI:2.5-5.1)in 1989-1994,and 5.1 mo(95%CI:4.3-5.9)in 2010-2014(logrank P=0.26).CONCLUSION OS significantly improved in non-metastatic proximal esophageal cancer,likely to be associated with an increased use of CRT.Patterns in metastatic disease did not change significantly over time. | Judith de Vos-Geelen Sandra ME Geurts Liselot BJ Valkenburg-van Iersel Evelien JM de Jong Vivianne CG Tjan-Heijnen Margreet van Putten Valery EPP Lemmens Heike I Grabsch Nadia Haj Mohammad Frank JP Hoebers Chantal V Hoge Paul M Jeene Hanneke WM van Laarhoven Tom Rozema Marije Slingerland Grard AP Nieuwenhuijzen | 2019 | World Journal of Gastroenterology2019，25，47： | 2 |
| 2 | Drone- darone acts as a selective inhibitor of 3,5,3 '- triio- dothyronine binding to thyroid hormone receptor, al- phal: in vitro and in vivo evidenee 显示文摘 | Van Beeren HC Jong WM Kaptein E | 2003 | Endocrinolo- gy2003，144，2： | 1 |
| 3 | Liquid chromatographic analysis of alizapride and metoclopramide in human plasma and urine using solid-phase extraction显示文摘 | de Jong AP Wittebrood AJ du Chatinier WM | 1987 | J Chromatogr1987，419，： | 1 |
| 4 | Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria显示文摘 | Monster TB Janssen WM de Jong PE | 2001 | Arch Intern Med2001，161，16： | 1 |
| 5 | Barrett's oe- sophagus: epidemiology, cancer risk and implications for manage- ment显示文摘 | de Jonge PJ van Blankenstein M Grady WM | 2014 | Gut2014，63，1： | 1 |
| 6 | Organic anion transporter 1Bl:an important factor in hepatic thyroid hormone and estrogen transport and metabolism显示文摘 | van der Deure WM Friesema EC de Jong FJ | | 0，，： | 1 |
| 7 | Dronedarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alphal:in vitro and in vivo evidence显示文摘 | Van Beeren HC Jong WM Kaptein E | 2003 | Endocrinology2003，144，2： | 1 |
| 8 | Hypertension and renal disease: role of Microalbuminuria显示文摘 | Janssen WM de Jong PE de Zeeuw D | 1966 | J Hypertens Suppl1966，14，5： | 1 |
| 9 | Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease显示文摘 | Kooloos WM de Jong DJ Huizinga TWJ | 2007 | Drug Discov Today2007，12，34： | 1 |
| 10 | Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria 显示文摘 | Monster TB Janssen WM de Jong PE | 2001 | Arch Intern Med2001，161，16： | 1 |
| 11 | Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease显示文摘 | Kooloos WM de Jong DJ Huizinga TWJ | | 0，，： | 1 |
| 12 | Mucopolysaccharidoses screening, dimethylmethytene blue versus aleian blue显示文摘 | de Jong JG Heijs WM Wevers RA | 1994 | Ann Clin Bioehem1994，31，3： | 1 |
| 13 | Ophthalmic acid as a read-out for hepatic glutathione metabolism in humans显示文摘Background and Aim:Animal studies indicated that systemic ophthalmic acid(OPH)is a biomarker for hepatic glutathione(GSH)homeostasis,an important determinant of liver function.We aimed to clarify whether OPH levels can be used as a read-out for hepatic GSH homeostasis after paracetamol(APAP)challenges during pylorus-preserving pancreaticoduodenectomy(PPPD)or partial hepatectomy(PH).Methods:Nineteen patients undergoing PPPD(n=7,control group)or PH(n=12)were included.APAP(1000 mg)was administered intravenously before resection(first challenge),and six and twelve hours later,with sequential blood sampling during this period.Arterial,hepatic and portal venous blood samples and liver biopsies were taken on three occasions during the first APAP challenge.Plasma and hepatic OPH and GSH levels were quantified,and venous-arterial differences were calculated to study hepatic release.Results:Systemic GSH levels decreased during the course of the APAP challenge in both surgical groups,without notable change in OPH levels.Hepatic GSH and OPH content was not affected within^3 hours after administration of the first APAP dose in patients undergoing PPPD or PH.In this period,net release of OPH by the liver was observed only in patients undergoing PPPD.Conclusions:The drop in circulating GSH levels following APAP administrations,did not result in an increase in plasma OPH in both patients with an intact liver and in those undergoing liver resection.Hepatic content of GSH and OPH was not affected during the first APAP dose.It is uncertain whether hepatic GSH homeostasis was sufficiently challenged in the present study.Relevance for patients:In the present study,plasma OPH seemed not useful as a marker for GSH depletion because APAP administration during liver surgery did not lead to(immediate)GSH depletion or increased OPH levels.Based on stable levels of hepatic GSH,OPH and thiyl radicals during surgery,standard APAP administration seems to be safe in a postoperative care program with regards to GSH homeostasis in this specific population.However,no general statements can be made on the basis of the current experiment,since GSH homeostasis and susceptibility to xenobiotic toxicity are influenced by several metabolic and genetic factors. | Kim MC van Mierlo Simon AWG Dello Mechteld C de Jong Hans MH van Eijk Theo M de Kok Jacob J Briedé Frank G Schaap Steven WM Olde Damink Cornelius HC Dejong | 2017 | Journal of Clinical & Translational Research2017，3，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员